The project builds on work at the university to understand the role apelin receptors play in cardiovascular diseases. The collaboration gives Heptares access to a group run by Anthony Davenport,
The drug is approved as the first adjunctive therapy in the European Union (EU) for patients aged two years and older. The EC’s decision marks the third TSC-related
EyeGate OBG is being developed to accelerate re-epithelialization of large corneal epithelial defects Following the findings from the results, EyeGate intends to further develop the gel with a double-masked
The approval is based on a large clinical database, comprising data from over 1,300 patients with cUTI across phase 3 studies, including several patients with infections due to
It is the first adalimumab biosimilar candidate recommended for EMA approval. It has been recommended to treat certain inflammatory ailments in adults like moderate-to-severe rheumatoid arthritis, severe ankylosing spondylitis
The committee recommended approval of Xeljanz (tofacitinib citrate) in combination with methotrexate (MTX) for the treatment of adults with moderate to severe active RA who have not responded
PF-06425090, following the findings from the pre-planned interim analysis, will now progress towards a phase 3 trial, slated to be initiated in the first half of this year.
Actelion discovers, develops and commercializes new drugs for diseases with significant unmet medical need. As part of the deal, Actelion will spin out its drug discovery operations and
The options range from retaining the business to separation through a capital markets transaction in order to identify how to best maximize value for the company’s shareholders. Alcon
Dubbed ReLive, the phase 3 trial will evaluate the efficacy of intravenous (IV) administration of Livatag for treating the aggressive form of primary liver cancer. It will have patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.